Clinical Review 134: The endocrinology of prostate cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 8, 2001, Pages 3467-3477

  Taplin, Mary Ellen ^a   Ho, Shuk Mei ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIOL; BICALUTAMIDE; CALCITRIOL; DIETHYLSTILBESTROL; ESTRAMUSTINE; ESTROGEN RECEPTOR; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HYDROCORTISONE; ISOTRETINOIN; KETOCONAZOLE; MEGESTROL; NILUTAMIDE; PRASTERONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; STEROID 5ALPHA REDUCTASE INHIBITOR; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

CARCINOGENESIS; CASTRATION; CLINICAL TRIAL; DNA POLYMORPHISM; GENE MUTATION; GYNECOMASTIA; HORMONE SYNTHESIS; HUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; WITHDRAWAL SYNDROME;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; HUMANS; MALE; MODELS, BIOLOGICAL; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN;

EID: 0034880266     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.8.3467     Document Type: Review

References (170)

1. Cancer statistics, 2000
2. The effect of castration, of oestrogen and of androgen injections on serum phosophatases in metastatic carcinoma of the prostate
3. The molecular biology, endcrinology and physiology of the prostate and seminal vesicles
4. Endocrinology of the prostate
5. Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer
6. The physical state of testosterone in plasma
7. Structure of human type II 5 α-reductase gene
8. Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia
9. Characterization of 5α-reductase gene expression in stroma and epithelium of human prostate
10. Prostate cancer prevention trials in the USA
11. Local estrogen biosynthesis in males and females
12. Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma
13. Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer
14. Aromatase in hyperplasia and carcinoma of the human prostate
15. Role of estrogens in human benign prostatic hyperplasia
16. A and B forms of the androgen receptor are present in human genital skin fibroblasts
17. Impotence therapy and cancer of the prostate
18. Prostatic complications of testosterone replacement therapy
19. Adenocarcinoma of prostate in 40-year-old body-builder
20. Effects of prenatal maternal estrogen on the male urogenital system
21. Neoplastic transformation of the prostate
22. The role of steroid hormones in prostate carcinogenesis
23. The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate
24. Relationships of serum androgens and estrogens to prostate cancer risk: Results from a prospective study in Finland
25. Prospective study of sex hormone levels and risk of prostate cancer
26. Serological precursors of cancer: Serum hormones and risk of subsequent prostate cancer
27. Prediagnostic serum hormones and the risk of prostate cancer
28. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study
29. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate
30. Serum testosterone levels in healthy young black and white men
31. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: Results from the Dutch-Japanese case-control study
32. 5-alpha-reductase activity and risk of prostate cancer among Japanese and U.S. white and black males
33. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada
34. The early in utero oestrogen and testosterone environment of blacks and whites: Potential effects on male offspring
35. Environmental factors, hormone status, and prostatic cancer
36. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer
37. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA
38. Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk
39. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
40. Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations
41. Genetic variation of 3 β-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: Implications for prostate cancer risk
42. Dinucleotide repeat polymorphisms in the HSD3B2 gene
43. The steroid and thyroid hormone receptor superfamily
44. The steroid receptor superfamily: More excitement predicted for the future
45. Receptor proteins for androgens. On the role of specific proteins in selective retention of 17-β-hydroxy-5-α-androstan-3-one by rat ventral prostate in vivo and in vitro
46. Molecular cloning of human and rat complementary DNA encoding androgen receptors
47. Cloning of human androgen receptor complementary DNA and localization to the X chromosome
48. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1
49. Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines
50. Characterization of the human androgen receptor transcription unit
51. Cloning, structure and expression of a cDNA encoding the human androgen receptor
52. Molecular biology of the androgen receptor
53. Receptor proteins for androgens. On the role of specific proteins in selective retention of 17-β-hydroxy-5-α-androstan-3-one by rat ventral prostate in vivo and in vitro
54. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
55. Nuclear import of the human androgen receptor
56. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor
57. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization
58. Androgen receptor - An update of mechanisms of action in prostate cancer
59. Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry
60. Intracellular localization and trafficking of steroid receptors
61. Androgen-regulated gene expression in prostate cancer
62. Androgen receptors in endocrine-therapy-resistant human prostate cancer
63. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate
64. Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates
65. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis
66. Neuroendocrine cells in tumour growth of the prostate
67. Do neuroendocrine cells in human prostate cancer express androgen receptor?
68. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation
69. Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4, and CK1 p16 genes
70. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter
71. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer
72. Relation of Bcl-2 expression to androgen receptor, p21WAF1 /CIP1, and cyclin D1 status in prostate cancer
73. Transforming growth factor-β1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP
74. Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death
75. Transforming growth factor-β1 and prostate cancer
76. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy
77. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor
78. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts
79. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients
80. Novel strategies and therapeutics for the treatment of prostate carcinoma
81. Molecular implications of the antiandrogen withdrawal syndrome
82. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
83. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma
84. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer
85. Update of the androgen receptor gene mutations database
86. Identification of two germline point mutations in the 5′UTR of the androgen receptor gene in men with prostate cancer
87. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone
88. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor
89. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol
90. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer
91. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
92. Studies on the human prostatic cancer cell line LNCaP
93. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
94. Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men
95. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis
96. Androgen receptor mutations in prostate cancer
97. Androgen receptors in prostate cancer
98. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers
99. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
100. Prostate cancer schemes for androgen escape
101. Hyperactive androgen receptor in prostate cancer: What does it mean for new therapy concepts?
102. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
103. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer
104. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer
105. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
106. Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset
107. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population
108. The androgen receptor gene GGN microsatellite and prostate cancer risk
109. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk
110. Microsatellite mutation (CAG24→18) in the androgen receptor gene in human prostate cancer
111. Inhibition of p160-mediated coactivation with increasing and rogen receptor polyglutamine length
112. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
113. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
114. The role of the androgen receptor in the development and progression of prostate cancer
115. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways
116. Prostate cancer: Molecular biology of early progression to androgen independence
117. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer
118. Nuclear hormone receptor coregulators in action: Diversity for shared tasks
119. FHL2, a novel tissue-specific coactivator of the androgen receptor
120. Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators
121. Comparative studies of estrogen receptor-β, α and androgen receptor in normal human prostate glands, dysplasia and in primary and metastatic carcinoma
122. Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation
123. Vitamin D receptor polymorphisms as markers in prostate cancer
124. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population
125. Vitamin D and prostate cancer: Biologic interactions and clinical potentials
126. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms
127. New agents for chemoprevention of prostate cancer
128. Effects of pituitary hormones on the prostate
129. Dietary fat and protein intake differ in modulation of prostate tumor growth, prolactin secretion and metabolism, and prostate gland prolactin binding capacity in rats
130. A phase II study of bromocriptine in patients with androgen-independent prostate cancer
131. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions
132. Proliferative disorders of the aging human prostate: Involvement of protein hormones and their receptors
133. Molecular cloning of human prostate specific antigen cDNA
134. Value of molecular forms of prostate-specific antigen and related kallikrein, hK2, in diagnosis and staging of prostate cancer comprehensive
135. Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios
136. Prostate-specific antigen: A cancer fighter and a valuable messenger?
137. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas
138. Growth regulation of prostatic stromal cells by prostate-specific antigen
139. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy
140. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 NO MO prostatic carcinoma
141. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
142. p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610
143. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer
144. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study
145. Intermittent androgen suppression in the management of prostate cancer
146. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-postitive prostate cancer
147. Receptor affinity and potency of non-steroid antiandrogens:translation of preclinical findings into clinical activity
148. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
149. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
150. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
151. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
152. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance
153. Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy
154. Androgen receptor analyses in androgen independent prostate cancer (AIPCA): Cancer and Leukemia group B (CALGB) 9663
155. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy
156. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease
157. Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation
158. Aminoglutethimide and ketoconazole: Historical perspectives and future prospects
159. The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma
160. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer
161. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: Simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal
162. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma
163. Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer
164. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells
165. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer
166. A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma
167. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES
168. Activity of the herbal combination, PC-SPEC, in the treatment of patients with androgen-independent prostate cancer
169. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and leukemia group B study 9181
170. A Phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer